KALA BIO Shares Surge 35% on Oxford Finance Stake and KPI-012 Progress

Introduction

KALA BIO INC (ticker: KALA) is a clinical-stage biopharmaceutical company headquartered in Arlington, Massachusetts. Established in 2009, KALA BIO utilizes its proprietary mesenchymal stem cell secretome (MSC-S) platform to develop therapies for rare and severe eye diseases. The company’s lead candidate, KPI-012, is currently in a Phase 2b clinical study for persistent corneal epithelial defect (PCED) and has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration.

Corporate Structure

As of December 4, 2025, KALA BIO employs between two and ten professionals. The leadership team has significant experience in ophthalmic and biopharmaceutical sectors:

• Todd Bazemore, interim Chief Executive Officer (Feb 2025–Sep 2025) and former Chief Operating Officer (Nov 2017–Feb 2025), with over 30 years in therapies for rare and large-market conditions.
• Dr. Lloyd Brazzell, Chief Medical Officer since Feb 2013, with previous roles in clinical R&D at Inspire Pharmaceuticals and Novartis Ophthalmics.
• Additional senior executives with backgrounds in business development, finance, and operations from biotechnology and medical technology firms.

KALA BIO is publicly traded on the Nasdaq Stock Market (exchange code “NAS”).

Biopharmaceuticals by little plant

Recent Developments and News

• July 16, 2025: KALA BIO hosted a webcast featuring key opinion leaders, including Dr. Francis Mah (Scripps Clinic) and Dr. Anthony Aldave (UCLA), to discuss KPI-012's applications in PCED. An archived replay is available on the company’s website.
• November 19, 2025: KALA BIO filed Form 10-Q for the quarter ended September 30, 2025, which included details on operating expenses, net loss figures, and cash position.
• November 25, 2025: The company submitted a Current Report on Form 8-K disclosing governance matters, material agreements, and leadership updates.
• December 3, 2025: A Schedule 13G filing indicated that Oxford Finance LLC holds 1,620,000 shares, which represents a 16.5% stake in KALA BIO’s outstanding stock.
• December 4, 2025: KALA BIO shares closed at USD 1.2498, reflecting a 35.11% increase on a volume of 10,258,529 shares traded.

Financial and Strategic Analysis

KALA BIO’s market capitalization is approximately USD 7.6 million, with an enterprise value of USD 16.4 million. According to the September 30, 2025, 10-Q:

• Net loss (TTM): USD 35.8 million
• Cash and equivalents (mrq): USD 21.1 million
• Profit margin: 0.0%
• Return on assets (TTM): –65.8%

Following the sale of its commercial ophthalmic products to Alcon Inc. in July 2022, KALA BIO is now focused on its biologics pipeline. KPI-012 is aimed at addressing PCED, while KPI-014 targets inherited retinal degenerations with a gene-agnostic approach. The Orphan Drug and Fast Track designations indicate regulatory encouragement for KPI-012.

Market Position and Industry Context

KALA BIO operates within the market for rare ophthalmic diseases, where approved therapies for PCED and limbal stem cell deficiency (LSCD) are currently unavailable. The estimated annual incidence in the U.S. is approximately 100,000 patients for both PCED and LSCD. Inherited retinal diseases, such as retinitis pigmentosa, similarly affect a considerable number of patients but are often underserved by available treatments. KALA BIO’s MSC-S platform positions the company within a select group of organizations focused on regenerative ocular therapies. Being a small-cap biotechnology company, its stock may exhibit volatility linked to clinical and regulatory developments.

tl;dr

• On December 4, 2025, KALA BIO’s share price increased by 35.11% to USD 1.2498 on trading volume of 10.26 million shares.
• Oxford Finance LLC reported a 16.5% ownership stake (1.62 million shares) in a Schedule 13G filed on December 3, 2025.
• KPI-012 is currently in Phase 2b for PCED, with a potential readout anticipated as a key milestone.
• Cash balance of USD 21.1 million supports ongoing trials, and the strategic focus is on MSC-S biologics for rare eye diseases.